UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): ~~January~~March 1530, 2026

THERAPEUTICSMD, INC.

(Exact Name of Registrant as Specified in its Charter)

Nevada		001-00100		87-0233535
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

951 Yamato Road, Suite 220

Boca Raton, FL 33431

(Address of Principal Executive Office) (Zip Code)

Registrant’s telephone number, including area code: (561) 961-1900

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol		Name of Each Exchange on Which Registered
Common Stock, par value $0.001 per share		TXMD		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230-405) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 4 2.0102 ~~Changes~~Results inof ~~Registrant’s~~Operations ~~Certifying~~and ~~Accountant~~Financial Condition.

OnThe ~~January~~information ~~15,~~provided ~~2026,~~in ~~the~~Item ~~Audit Committee of the Board of Directors of TherapeuticsMD, Inc~~7.,01 ~~a Nevada corporation (the “Company”), approved the appointment~~ of ~~Carr, Riggs & Ingram, L.L.C.~~this ~~(“CRI”)~~Current asReport ~~the~~on ~~Company’s~~Form ~~independent~~8-K ~~registered~~is ~~public~~incorporated ~~accounting~~in ~~firm,~~this ~~effective~~Item ~~immediately~~2.02 Inby connection therewith, Berkowitz Pollack Brant Advisors + CPAs (“BPB”), the Company’s prior independent registered public accounting firm, ceased serving as the Company’s independent registered public accounting firm as a result of a transaction pursuant to which CRI acquired certain assets related to the capital markets practice of BPBreference.

~~BPB’s~~Item 7.01 ~~audit~~Regulation ~~reports~~FD on the Company’s consolidated financial statements for each of the fiscal years ended December 31, 2024 and December 31, 2023 did not contain an adverse opinion or a disclaimer of opinion, nor was it qualified or modified as to uncertainty, audit scope or accounting principles, except that BPB’s reports on the Company’s financial statements as of and for the fiscal years ended December 31, 2024 and December 31, 2023 included an explanatory paragraph describing the uncertainty of the Company’s ability to continue as a going concernDisclosure.

~~During~~On ~~the~~March ~~Company’s~~30, ~~fiscal years ended December 31~~2026, TherapeuticsMD, ~~2025 and~~Inc., ~~December~~a ~~31,~~Nevada ~~2024~~corporation ~~through~~ (the ~~date of dismissal: (1) there were no~~ “~~disagreements~~Company”), ~~(as~~issued ~~defined~~a inpress ~~Item~~release announcing ~~304(a)(1)(iv)~~its offinancial ~~Regulation S-K~~results ~~and~~for the ~~related~~full ~~instructions~~year ~~to Item 304) with BPB on any matter of accounting principles or practices, financial statement disclosure,~~ended orDecember ~~auditing scope or procedure~~31, ~~which~~2025. ~~disagreements,~~A copy ifof ~~not resolved to~~ the ~~satisfaction~~press ofrelease ~~BPB,~~is ~~would~~furnished ~~have~~as ~~caused~~Exhibit ~~BPB~~99.1 to ~~make~~this ~~reference to~~Current ~~the~~Report ~~subject matter of such disagreements in connection with its reports~~ on ~~the~~Form ~~financial~~8-K ~~statements for such periods,~~ and ~~(2)~~is ~~there~~incorporated ~~were~~herein noby ~~“reportable events” (as defined in Item 304(a)(1)(v) of Regulation S-K)~~reference.

The ~~Company~~information ~~provided~~in ~~BPB with a copy of~~ this ~~Current~~Item ~~Report~~7.01 onand ~~Form~~the information ~~8-K~~contained ~~(this~~in ~~“Report”)~~Exhibit ~~prior~~99.1 tois ~~its~~furnished ~~filing with the Securities~~ and ~~Exchange~~shall ~~Commission~~not ~~(the~~be deemed “~~SEC~~filed”) ~~and~~for ~~requested that~~purposes ~~BPB~~of ~~furnish~~Section 18 of the ~~Company~~Securities ~~with~~Exchange Act aof ~~letter~~1934, ~~addressed~~as toamended (the ~~SEC~~“Exchange ~~stating~~Act”), ~~whether~~or ~~BPB~~incorporated ~~agrees~~by ~~with~~reference ~~the~~in ~~statements~~any ~~made~~filing byunder the ~~Company~~Securities ~~in this~~Act ~~Report~~of ~~and~~1933, as ~~if not~~amended, ~~stating~~or the ~~respects,~~Exchange ~~if any~~Act, inexcept ~~which~~as ~~BPB~~may ~~does~~be ~~not~~expressly ~~agree~~set ~~with~~forth ~~such~~by ~~statements.~~specific ~~The~~reference ~~letter~~in ofany ~~BPB~~such ~~addressed~~filing, ~~to the~~regardless ~~Securities~~of ~~and~~any ~~Exchange~~general incorporation ~~Commission~~language isin ~~attached~~the ~~hereto as Exhibit 16~~filing.1.

~~During~~The ~~the~~Company ~~years~~does ~~ended~~not ~~December 31~~have, ~~2025~~ and ~~December~~expressly 31disclaims, ~~2024 and~~ ~~through~~any ~~the~~obligation ~~date~~to ofrelease ~~their~~publicly ~~appointment,~~any ~~neither~~updates ~~the~~or ~~Company~~any ~~nor~~changes ~~anyone~~in ~~acting on~~ its ~~behalf~~expectations ~~consulted~~or ~~with~~any ~~CRI~~change ~~regarding:~~in ~~(i) the application of accounting principles to a specified transaction~~events, ~~either completed or proposed~~conditions, or ~~the type of audit opinion that might be rendered~~circumstances on ~~the~~which Company’s financial statements, and neither a written report nor oral advice was provided to the Company that CRI concluded was an important factor considered by the Company in reaching a decision as to the accounting, auditing or financial reporting issue; or (ii) any ~~matter that was either the subject of a “disagreement” within the meaning of Item 304(a)(1)(iv) of Regulation S~~forward-Klooking ~~and~~statement ~~the~~is ~~related instructions to Item 304 or a “reportable event” within the meaning of Item 304(a)(1)(v) of Regulation S-K~~based.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Index

Exhibit No.		Description
16.1		Letter from Berkowitz Pollack Brant Advisors + CPAs to the Securities and Exchange Commission, dated January 20, 2026.
99.1		Press Release from TherapeuticsMD, Inc., dated March 30, 2026, entitled “TherapeuticsMD Announces Full Year 2025 Financial Results”
104		Cover Page Interactive Data File (the cover page tags are embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 20, 2026	THERAPEUTICSMD, INC.
Date: March 30, 2026	THERAPEUTICSMD, INC.
	/s/ Marlan Walker
	Marlan Walker
	Chief Executive Officer

Filing Compare · TherapeuticsMD, Inc.